Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Nov
19
Today In Oncology
Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation
My 50 Years in Lymphoma: Lessons Learned?
Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma
Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer
Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo